Tuesday, November 24, 2009, 3:27AM AEST - The Australian Stockmarket opens in 6 hours and 33 minutes.
To create a watchlist or portfolio of shares, Register

ARYx Therapeutics, Inc. (ARYX)

3:05AM AEST: 2.45 USD  Down 0.01 (0.41%)  
 MORE ON ARYX 
Quotes
HereSummary
Charts
Technical Analysis
News & Info
Company
Analyst Coverage
Ownership
Financials
 ARYx Therapeutics, Inc. (NGM:ARYX) Delayed quote dataEdit
Last Trade:2.45 USD
Trade Time: 3:05AM AEST
Change:Down 0.01 (0.41%)
Prev Close:2.46
Open:2.49
Bid:2.45 x 100
Ask:2.47 x 100
1y Target Est:6.38
Day's Range:2.45 - 2.50
52wk Range:1.10 - 6.32
Volume:7,929
Avg Vol (3m):77,180.3
Market Cap:67.59M
P/E (ttm):N/A
EPS (ttm):-1.54
Div & Yield:N/A (N/A%)
[Chart]
1d  5d  3m  6m  1y  2y  5y 
 Add ARYX to Portfolio   Download Data

 HEADLINES 
ARYX THERAPEUTICS, INC. Financials
EDGAR Online Financials (Thu, Nov 19)
Results From Phase 2b Study on Atrial Fibrillation Agent Reviewed at American Heart Association
Business Wire (Wed, Nov 18)
New Star Analyst Rankings for ARYx Therapeutics, Inc.
StarMine (Mon, Nov 16)
ARYX THERAPEUTICS, INC. Files SEC form 10-Q, Quarterly Report
EDGAR Online (Fri, Nov 13)
Aryx Therapeutics reports $8.2M loss
at bizjournals.com (Fri, Nov 13)
Third Quarter 2009 Results and Earnings Call scheduled for 11:00 am ET today
Shareholder.com (Fri, Nov 13)
ARYx Therapeutics Reports Third Quarter 2009 Results
Business Wire (Fri, Nov 13)
Q3 2009 ARYx Therapeutics Earnings Release - Time Not Supplied
CCBN (Thu, Nov 12)
ARYX THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and E
EDGAR Online (Thu, Nov 12)
ARYx Therapeutics Schedules Third Quarter 2009 Results Conference Call
Business Wire (Fri, Nov 6)
More Headlines for ARYX...

 ANALYST 
EPS Est (next year) (Dec-09) :-1.11
EPS Est (in 2 years) (Dec-10) :-0.27
Avg Rec (current)*:1.3
PEG Ratio:N/A
* (Strong Buy) 1.0 - 5.0 (Strong Sell)
Analyst Opinion - Estimates

 BUSINESS SUMMARY 
ARYx Therapeutics, Inc., a biopharmaceutical company, focuses on developing a portfolio of product candidates designed to eliminate known safety issues associated with commercial drugs using its RetroMetabolic Drug Design technology.

Full Company Profile



Add to My Portfolio Add to Portfolio    Email to a Friend Email to a Friend
Get Summary for Another Symbol:
Symbol Lookup
Latest News7 Indices